🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exciting manuscript from @Absci - generative AI models are accelerating the drug creation process and potentially improving outcomes! absci.com/absci-achieves…

Looking forward to speaking today at the JMP Securities Life Science Conference at 230 ET. Join the webcast to learn more about our mission to advance next-gen cell and gene therapies using our gene-circuit platform: bit.ly/3V8ER7S #biotech #celltherapy Senti Biosciences $SNTI

Congratulations to the OpenProtein.AI team and tbepler on this exciting new publication. Opportunities for ML-driven protein design continue to grow!

Nature research paper: Sub-1.4 cm3 capsule for detecting labile inflammatory biomarkers in situ go.nature.com/44YF29F

Really excited to publish this work with Maria Eugenia Inda, Gio Traverso, Rabia Yazicigil, and other colleagues advancing a miniaturized pill with living cells for sense-and-respond in vivo!

Exciting times for Senti Biosciences as we gain extra fuel to power our Gene Circuit enhanced cell therapies to patients.

Check out how $SNTI's Logic Gates precisely discriminate between cancer cells and healthy cells, allowing us to achieve highly precise cancer therapeutics! #synbio

We Absci are excited to unveil IgDesign™ NeurIPS Conference and present our work at MLSB @ NeurIPS NeurIPS AI4D3 Workshop GenBio Workshop @Neurips2023! IgDesign is an antibody inverse folding model that we have experimentally validated in our lab. Read the paper here: biorxiv.org/content/10.110… #NeurIPS2023

Congratulations to Senti Biosciences for its $8M award from California Institute for Regenerative Medicine (CIRM) for its Logic-Gated SENTI-202 clinical trial for relapsed/refractory AML. Thanks so much to CIRM for this support! $SNTI cirm.ca.gov/about-cirm/new…

Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: bit.ly/4eUaKtb $SNTI

Excited to share the detailed data on SENTI-202 with Dr. Stephen Strickland and Dr. Kanya Rajangam. Join us to learn about how our #genecircuits enhanced CAR-NK therapies have the potential to transform the treatment of cancer through Logic Gating. $SNTI

Very excited to share details on SENTI-202 clinical trial - 2 of 3 pts achieved MRD negative CR in 1st dose level evaluated with a generally well-tolerated preliminary safety profile. Both patients continue to maintain remission (4+ and 3+ months, respectively). $SNTI